Amplification of the 3q chromosomal region as a specific marker in cervical cancer

Compagno, John; Romano, P. Martin; Grazioli, Vittorio; Verma, Yogita; Kershnar, Eric; Tafas, Triantafyllos; Kilpatrick, Michael W.

doi:10.1016/j.ajog.2015.02.001

Cited by 15 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Changes in chromosome 3 have been extensively reported for cervical cancer. Gain of chromosome 3q has been reported in pre-cancer and cancer of the cervix (these are some of the reports: [ 58 , 59 , 60 , 61 ]) while loss of 3p12-p14 has also been observed [ 62 ] and loss of heterozygosity on chromosome 3p has been also reported in this cancer [ 55 ].…”

Section: Results For Cervix Cancermentioning

confidence: 99%

An Optimization-Driven Analysis Pipeline to Uncover Biomarkers and Signaling Paths: Cervix Cancer

et al. 2015

View full text Add to dashboard Cite

Establishing how a series of potentially important genes might relate to each other is relevant to understand the origin and evolution of illnesses, such as cancer. High-throughput biological experiments have played a critical role in providing information in this regard. A special challenge, however, is that of trying to conciliate information from separate microarray experiments to build a potential genetic signaling path. This work proposes a two-step analysis pipeline, based on optimization, to approach meta-analysis aiming to build a proxy for a genetic signaling path.

show abstract

Section: Results For Cervix Cancermentioning

confidence: 99%

An Optimization-Driven Analysis Pipeline to Uncover Biomarkers and Signaling Paths: Cervix Cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Regarding the relation between HPV infection and 3q26/hTERC gaing, it is debated whether 3q26/hTERC gain a direct cause of HPV infection, or an independent risk factor in high-grade CIN. It has been shown that genomic integration of HPV (with increased expression of E6 and E7) and gain of hTERC are important associated genetic events in the progression of CIN to cervical cancer [ 16 ]. On the other hand, 3q gains have also been detected in non-HPV-associated squamous cell cancers of the lower genital tract and other malignancies [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

“…Overexpression of hTERC leads to the avoidance of abnormal cells with critically short telomeres to undergo apoptosis, which is a contributing factor in oncogenesis. Gain of 3q26/hTERC or copy number variations has been shown to correlate with disease grade in cervical lesions and could function as a diagnostic tool in cervical pathology [13–16]. Several studies have addressed the prognostic properties of 3q26/hTERC gain in the natural prognosis of CIN, but most studies focussed on low-grade lesions and/or evaluated 3q gain in cytological specimen.…”

Section: Introductionmentioning

confidence: 99%

Gain of Chromosomal Region 3q26 as a Prognostic Biomarker for High-Grade Cervical Intraepithelial Neoplasia: Literature Overview and Pilot Study

Koeneman

Øvestad

Janssen

et al. 2018

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Approximately 20–40% of high-grade Cervical Intraepithelial Neoplasia (CIN) regresses spontaneously, but the natural prognosis of an individual lesion is unpredictable. Gain of the chromosomal 3q region, which contains the human telomerase RNA gene on 3q26 , is found in CIN lesions and cervical carcinoma and shows correlation with disease grade. The aim of this study is to assess whether 3q26 gain as a single genetic marker can predict the natural prognosis of high-grade CIN, by performing a review of the literature and pilot study. A literature review was conducted. Additionally, we performed a pilot study in 19 patients with histologically confirmed high-grade CIN lesions who were followed for a mean of 115 days, after which loop excision was performed. Fluorescent in situ hybridization analysis was performed on the initial diagnostic biopsies to determine gain of 3q26 . Eight studies were included in the literature overview, with a total of 407 patients. Of these, only 22 patients had high-grade lesions. All studies found an association between 3q26 gain and disease prognosis. Positive predictive values (PPV) ranged from 50 to 93%, negative predictive values (NPV) ranged from 75 to 100%. Only five out of 155 patients (3.2%) without 3q26 gain showed disease persistence or progression. In our pilot study on 3q26 gain in high-grade CIN, the PPV of 3q26 gain for disease persistence was 67%, the NPV 100%. All four patients without 3q26 gain showed disease regression. In conclusion, the absence of 3q26 gain in diagnostic biopsies may be applied to identify high-grade CIN lesions with a high probability of disease regression.

show abstract

“…Several other microscopy-based strategies have been suggested for application in cervical cancer screening, such as the detection of a gain of chromosome 3q or the human telomerase gene (TERC) in cytological specimens by fluorescence in situ hybridization [71][72][73][74]. To the best of our knowledge, these strategies have not yet been evaluated in sufficiently large clinical cohorts of hrHPV-positive women.…”

Section: Other Microscopy-based Strategiesmentioning

confidence: 99%

Management of high-risk HPV-positive women for detection of cervical (pre)cancer

Luttmer

Strooper

Steenbergen

et al. 2016

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Introduction: Primary HPV-testing has been shown to provide a superior detection of women at risk of cervical (pre)cancer compared to cytology-based screening. However, as most high-risk HPV infections are harmless, additional triage testing of HPV-positive women is necessary to identify those with cervical (pre)cancer. In this paper, we compare the performance, advantages and limitations of clinically relevant available triage strategies for HPV-positive women. Areas covered: Many different colposcopy triage strategies, comprising both microscopy-based and molecular (virus/host-related) markers, have been suggested: Pap cytology, p16/Ki-67 dual-stained cytology, HPV16/18 genotyping, viral DNA methylation and host cell DNA methylation. Literature search was limited to triage strategies that have achieved at least phase 2 of the five-phase framework for biomarker development and studies including large cohorts (≥100 hrHPV-positive women). Triage markers were stratified by sample type (cervical scrape, self-collected sample) and by study population (screening, non-attendee, referral). Expert commentary: At present, repeat Pap cytology and Pap cytology combined with HPV16/18 genotyping are the only triage strategies that have been robustly shown to be ready for implementation. Other strategies such as p16/Ki-67 dual-stained cytology and host cell DNA methylation analysis, with or without additional HPV16/18 genotyping, are attractive options for the near future. ARTICLE HISTORY

show abstract

Amplification of the 3q chromosomal region as a specific marker in cervical cancer

Cited by 15 publications

References 20 publications

An Optimization-Driven Analysis Pipeline to Uncover Biomarkers and Signaling Paths: Cervix Cancer

An Optimization-Driven Analysis Pipeline to Uncover Biomarkers and Signaling Paths: Cervix Cancer

Gain of Chromosomal Region 3q26 as a Prognostic Biomarker for High-Grade Cervical Intraepithelial Neoplasia: Literature Overview and Pilot Study

Management of high-risk HPV-positive women for detection of cervical (pre)cancer

Contact Info

Product

Resources

About